Lets assume that liver transplant recipients in the study were categorized as alive instead of deceased. In my opinion it's very likely that the DUR-928 2b trial would have achieved a statistically significant difference in the 90-day mortality endpoint. Here's why:
Mortality Reduction: The initial results show a clinically meaningful reduction in 90-day mortality for both dosages:
41% reduction for the 30mg dose (p-value = 0.070)
35% reduction for the 90mg dose (p-value = 0.126)
Transplants as a Lifesaving Intervention: Liver transplants are performed in severe AH cases to prevent imminent death. Again in my opinion by including successful transplants in the "alive" category, we are essentially factoring in the positive impact larsucosterol could have on disease progression and the need for this critical intervention.